Efficacy News and Research

RSS

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer.

30 Aug 2011

U-M's minimally invasive revascularization procedure can treat peripheral arterial disease

Henry Gibbs, 58, is a ballroom dance instructor, but he was forced to hang up his dancing shoes when a circulation condition, common among older adults, caused severe leg pain and cramping.

29 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Philips to launch first sleep apnea mobile app at ESC 2011 congress

Royal Philips Electronics will provide clinicians from across the globe with a glimpse of future innovations designed to advance cardiac care, including the current management of cardiovascular disease (CVD) and associated cardiac conditions, during the 2011 Congress of the European Society of Cardiology (ESC), which opens today in Paris.

From Philips Healthcare 29 Aug 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.

29 Aug 2011

Everolimus-eluting stent and SES are equally effective for PCI patients

The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.

29 Aug 2011

EAS/ESC develops new dyslipidaemias guidelines

Clinicians should aim for comprehensive lipid control using lifestyle as a first step and tailoring treatment to patients. Lifestyle interventions, including stopping smoking, improving diet, exercising sufficiently and moderate alcohol consumption, should be the crucial first step for managing lipids in all patients.

29 Aug 2011

Sutureless method for reconnecting blood vessels

Reconnecting severed blood vessels is mostly done the same way today - with sutures - as it was 100 years ago, when the French surgeon Alexis Carrel won a Nobel Prize for advancing the technique.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

MitraClip treatment could benefit heart failure patients who are unresponsive to CRT

Results of an observational study presented at the European Society of Cardiology (ESC) meeting today in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular (LV) remodeling in patients with mitral regurgitation (MR), who do not respond to cardiac resynchronization therapy.

29 Aug 2011

Colchicine more effective than placebo for recurrent pericarditis

Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Severe combined immunodeficiency treated successfully with gene therapy

Gene therapy can offer a cure for a rare condition that causes children’s immune systems to fail. In this rare condition, known as Severe Combined Immunodeficiency (SCID), inherited genetic mutations mean that babies are unable to fight off infection, severely limiting their chances of surviving more than a few years. Severe combined immunodeficiency (SCID) is a rare genetic disorder estimated to affect between 1 in 200,000 and 1 in 1,000,000 live births

26 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

CVRx introduces CE Mark approved Barostim neo for treatment of uncontrolled hypertension

CVRx, Inc., a private medical device company, introduced today its second-generation implantable device, the Barostim neo, for the treatment of uncontrolled hypertension. The Barostim neo features a new unilateral, 1mm electrode and a new smaller, more advanced stimulator to allow for more focused and efficient delivery of therapy. These improvements have led to shorter procedure times and extended longevity.

25 Aug 2011

Achievement of physical activity goals linked to reduced arthritis pain, increased quality of life

Researchers from The Netherlands report that patients with rheumatoid arthritis (RA) who have higher levels of self-efficacy for physical activity are more likely to achieve their physical activity goals.

25 Aug 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

Efficacy News and Research

Magnetic resonance imaging may predict survival in patients with advanced rectal cancer

U-M's minimally invasive revascularization procedure can treat peripheral arterial disease

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Philips to launch first sleep apnea mobile app at ESC 2011 congress

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

Everolimus-eluting stent and SES are equally effective for PCI patients

EAS/ESC develops new dyslipidaemias guidelines

Sutureless method for reconnecting blood vessels

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

MitraClip treatment could benefit heart failure patients who are unresponsive to CRT

Colchicine more effective than placebo for recurrent pericarditis

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Severe combined immunodeficiency treated successfully with gene therapy

Firazyr receives FDA approval for treatment of HAE acute attacks

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

CVRx introduces CE Mark approved Barostim neo for treatment of uncontrolled hypertension

Achievement of physical activity goals linked to reduced arthritis pain, increased quality of life

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News